Literature DB >> 17549590

Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity.

M Otto1, S H Hansen, L Dalgaard, J Dubois, L Badolo.   

Abstract

In a number of adverse drug reactions leading to hepatotoxicity drug metabolism is thought to be involved by generation of reactive metabolites from nontoxic drugs. In this study, an in vitro assay was developed for measurement of the impact of metabolic activation of compound on the cytotoxicity toward a human hepatic cell line. HepG2 cells were treated for 6 h with compound in the presence or absence of rat liver S9-mix, and the viability was measured using the MTT test. The cytotoxicity of cyclophosphamide was substantially increased by S9-mix in the presence of NADPH. Three NADPH sources were tested: NADPH (1 mmol/L) or NADPH regenerating system with either NADP(+)/glucose 6-phosphate (G6P) or NADP(+)/isocitrate. All three NADPH sources increased the cytotoxicity of cyclophosphamide to a similar extent. Eight test compounds known to cause hepatotoxicity were tested. For these, only the cytotoxicity of diclofenac was increased by S9 enzymes when an NADPH regenerating system was used. The increased toxicity was NADPH dependent. Reactive drug metabolites of diclofenac, formed by NADPH-dependent metabolism, were identified by LC-MS. Furthermore, an increase in toxicity, not related to enzymatic activity but to G6P, was observed for diclofenac and minocycline. Tacrine and amodiaquine displayed decreased toxicity with S9-mix, and carbamazepine, phenytoin, bromfenac and troglitazone were nontoxic at all tested concentrations, with or without S9-mix. The results show that this method, with measurement of the cytotoxicity of a compound in the presence of an extracellular metabolizing system, may be useful in the study of cytotoxicity of drug metabolites.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549590     DOI: 10.1007/s10565-007-9018-x

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  5 in total

1.  Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.

Authors:  Alex G Peniche; Yaneth Osorio; Adam R Renslo; Doug E Frantz; Peter C Melby; Bruno L Travi
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

2.  High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.

Authors:  Seok Joon Kwon; Dong Woo Lee; Dhiral A Shah; Bosung Ku; Sang Youl Jeon; Kusum Solanki; Jessica D Ryan; Douglas S Clark; Jonathan S Dordick; Moo-Yeal Lee
Journal:  Nat Commun       Date:  2014-05-06       Impact factor: 14.919

3.  Characterization of In Vitro 3D Cell Model Developed from Human Hepatocellular Carcinoma (HepG2) Cell Line.

Authors:  Martina Štampar; Barbara Breznik; Metka Filipič; Bojana Žegura
Journal:  Cells       Date:  2020-11-28       Impact factor: 6.600

4.  Comparative study of the cytotoxicity and genotoxicity of alpha- and Beta-asarone.

Authors:  Pascal Unger; Matthias F Melzig
Journal:  Sci Pharm       Date:  2012-05-31

Review 5.  The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development.

Authors:  Paul A Walker; Stephanie Ryder; Andrea Lavado; Clive Dilworth; Robert J Riley
Journal:  Arch Toxicol       Date:  2020-05-06       Impact factor: 5.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.